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Key Points 
• All infants with in utero exposure to opioids demonstrate signs and symptoms of 
withdrawal.  Two thirds of infants require pharmacologic therapy to ensure proper 
feeding and development. 
• Opioid replacement is the optimal primary therapy.  The current standard is morphine, 
though there is significant heterogeneity in treatment regimens with many centers using 
methadone. 
• Of predictive factors, lack of poly-substance exposure, prematurity, and maternal use of 
buprenorphine are most strongly associated with less severe withdrawal symptoms and 
need for pharmacologic therapy. 
• Emerging therapies include the use of buprenorphine for primary therapy, and clonidine 
as an adjunct. 
• Pharmacogenetic profiling of infants and the use of modeling and simulation to optimize 
dosing are emerging, but not fully developed, technologies that may change the 
treatment of the neonatal abstinence syndrome. 
  
Synopsis 
Opioid use in pregnant women has increased over the last decade.  Following birth, infants with 
in utero exposure demonstrate signs and symptoms of withdrawal known as the neonatal 
abstinence syndrome.  Infants express a spectrum of disease, with most requiring the 
administration of pharmacologic therapy to ensure proper growth and development.  Treatment 
is generally as an inpatient and often involves prolonged hospitalization.  There is a general lack 
of high quality clinical trial data to guide optimal therapy, and significant heterogeneity in 
treatment approaches.  The balance of evidence favors morphine therapy titrated to symptom 
control and gradually weaned. Therapy with phenobarbital or clonidine is used as an adjunct in 
severe disease, or occasionally as initial therapy.  Poly-substance exposure in utero is 
associated with more severe symptoms and longer hospitalizations.  Breastfeeding is 
associated with better outcomes and should be strongly encouraged for all infants.  Emerging 
trends in the treatment of infants with the neonatal abstinence syndrome include the use of 
sublingual buprenorphine, transition to outpatient therapy, and pharmacogenetic risk 
stratification. 
Definition of NAS 
Neonatal withdrawal symptoms have been noted following prenatal exposure to a 
number of drugs.  Examples include opioids,[1, 2] benzodiazepines,[3, 4] mood stabilizing 
medications,[5] selective serotonin reuptake inhibitors,[6] and nicotine.[7]  For all drug classes 
except opioids, these symptoms are usually self-limited, and do not require pharmacologic 
treatment.  Infants born to mothers with opioid abuse or receiving methadone maintenance 
often develop withdrawal symptoms, following the postpartum cessation of in utero exposure to 
opioids.  This complex is known as the neonatal abstinence syndrome (NAS).  The full 
mechanistic basis for the clinical presentation is unclear.  Tolerance induced by long term 
exposure to opioids is primarily medicated by receptor downregulation coupled with 
upregulation in the cyclic adenosine monophosphate (cAMP) pathway. [8] Other mechanisms 
may include neuro-immune activation, production of anti-opioid peptides, or activation of the 
spinal dynorphin system.  Symptoms of withdrawal are are hypothesized to be due to increased 
adenylyl cyclase activity and an abrupt rise in norepinephrine following removal of the mu opioid 
ligand.  NAS is characterized by signs of central nervous system (CNS) hyper-irritability, 
gastrointestinal dysfunction, respiratory distress, and vague autonomic symptoms.  Common 
symptoms in order of frequency include tremors, high-pitched cry, sneezing, increased muscle 
tone, regurgitation, and vomiting, poor sleep, loose stools, sweating, excoriation, mottling, nasal 
stuffiness, low grade fever, and tachypnea.  Impaired weight gain and seizures are seen with 
untreated NAS.  All infants with prolonged in utero opioid exposure will develop signs and 
symptoms of withdrawal of varying severity.  However, the disorder encompasses a diverse 
spectrum, and those with milder symptoms respond well to supportive treatments.  NAS 
symptoms severe enough to require pharmacologic treatment occur in 55-94% of infants born to 
opioid-dependent mothers. [9] 
Current use of illicit drug occurs in 4.4% of pregnant women. [10] Heroin use during 
pregnancy is associated with fetal death and infant morbidity, including intrauterine growth 
retardation, placental insufficiency, postpartum hemorrhage, preeclampsia, and premature 
rupture of membranes. [11, 12] In an attempt to counter these poor outcomes, methadone 
maintenance in opioid-dependent pregnant females has been used for the past 35 years and is 
associated with improved birth weight and improvements in multiple domains. [13-16] A more 
recent development is the expansion in the use and abuse of prescription opioids.  While the 
use of heroin decreased by 19% between 1998 and 2008, abuse of prescription opioids during 
the same period increased by 41%. [17] In 2010, 5.1 million individuals reported nonmedical 
abuse of prescription pain medications within the previous month, with 71% of abused pain 
relievers being obtained from friends or family, and either bought or taken without permission. 
[10] The societal burden of NAS is difficult to assess, as is evident from the wide variations and 
implausible rates reported to regional authorities for hospitals in the defined geographic area 
with similar patient populations. [18] This is due to limited self-reporting of drug abuse, and 
underreporting of NAS using ICD classifications. [19]  In 1996, a National Institute of Drug 
Addiction (NIDA) survey estimated 7,000 cases occur each year, although the report conceded 
this is potentially an underestimation.[20]  More recently, the rate of NAS in the US has 
increased from 1.2 to 3.9 per 1,000 live births between 2000 and 2009. [21] A similar incident 
rate has been estimated in Australia. [22]   
 
Predictors of NAS severity 
The dose of maternal methadone dose as a covariate of the need for NAS treatment 
length has been examined extensively.  While a meta-analysis which evaluated studies by 
methodological quality did not identify a statistically significant difference in outcomes between 
high and low dose methadone, there is a suggestion of modest maternal dose dependency on 
outcomes.  [23] However, if such an effect does exist, it is small and not relevant in terms of 
choosing a maternal dose or differential treatment approaches in the treatment of infants. Lower 
maternal methadone doses have been associated with higher rates of illicit substitution, and a 
consensus view is that maternal doses of methadone should not be reduced solely to reduce 
NAS severity.  High quality randomized, controlled trial evidence from the MOTHER study has 
demonstrated that maternal buprenorphine compared to methadone use is associated with 
decreased need for morphine treatment in NAS and neonatal length of stay. [24] The maternal 
study population in this study has been convincingly demonstrated to be similar to the 
population at large, strongly supporting the generalizability of results. [25] 
While Jansson described worse NAS symptoms and pharmacotherapy in males, [26] 
severity, need for therapy or length of therapy were not influenced by gender in a cohort study 
by Holbrook. [27] Similarly, there was no sex dependency in the large randomized MOTHER 
study, which compared use of methadone and buprenorphine in pregnant females. [28] 
Intrapartum fetal heart rate variability or decelerations do not predict the need for therapy in 
NAS. [29] However, alternations in autonomic regulation, as measured by analysis of maternal 
[26] or infant [30] vagal tone have been noted to be predictors of worse NAS symptomatology.  
It is postulated that infants who adapt to maternal methadone -induced autonomic changes are 
maladapted to more severe NAS following birth.  Methadone exposure during pregnancy is 
associated with an approximately 2.5 fold increase in the rate of preterm birth. [31, 32] Preterm 
infants have a well-described natural history of NAS and a need for treatment that differs from 
term infants.  The current NAS scoring instruments have not been examined in this population. 
Need for therapy and [33] length of stay is shorter in the preterm population. [34, 35]  The 
preterm population thus appears to be categorically different in terms of in utero opioid 
exposure.   
Polydrug abuse during pregnancy is associated with impaired fetal markers (heart rate 
and variability) and greater need for postpartum pharmacologic therapy. [36] A retrospective 
study by Seligman demonstrated that the length of NAS treatment for all non-benzodiazepine 
exposed infants between 2000 and 2006 was 31 days, compared to 38 days for polydrug-
exposed term infants. [34] Strikingly, a multivariate analysis of infants revealed a significant 
prolongation of treatment duration for NAS (31 vs 47 days, P<0.01) of benzodiazepine vs. non-
benzodiazepine exposed infants.  Benzodiazepine withdrawal symptoms in adults include 
anxiety, tremors, anorexia, nausea, postural hypotension, and in severe cases, seizures, 
delirium, and hyperpyrexia.  The onset of symptoms is 12-24 hours for short acting agents with 
a peak at 72 hours, while longer acting agents such as diazepam are associated with an onset 
of 24-72 hours and a peak between 5 and 8 days following the last dose. [37] Benzodiazepines 
cross the placenta, [38, 39] but maternal confounders have made it difficult to estimate adverse 
effects specific to in utero exposure of benzodiazepines. [40] While teratogenicity is unlikely in 
benzodiazepine-exposed infants, [41-43] decreased birth weight and neonatal withdrawal have 
been noted, [3] the latter manifested by hypotonia and hypoventilation or tremulousness. [4] The 
half-life of diazepam in neonates is 31 days. [44] Thus, in contrast to that of adults, initiation of 
neonatal withdrawal for many benzodiazepines can be delayed with an onset at a week and 
effects noticeable for weeks. [45, 46]  There is no specific treatment for neonatal 
benzodiazepine withdrawal. Tobacco exposure is associated with the worse NAS 
symptomatology.  [47, 48] Analysis of meconium for tobacco, methadone or its metabolites, 
cocaine or opioids other than methadone, however, are not predictive of NAS outcomes. [49] 
 
Long and Short Term Sequelae 
Environmental and social factors are more important factors affecting childhood 
development than brief periods of pre-and peripartum exposure to drugs of abuse. [50, 51] 
Infants exposed in utero to opioids show low birth weights, increased preterm birth and reduced 
fetal growth parameters, but investigations have been hampered by the logistical difficulty of 
controlling for tobacco and other social factors associated with illicit drug use. [52] Studies which 
have linked in utero opioids to impaired neurodevelopment [53] have been criticized for not 
accounting for confounding of the child’s social and environmental milieu. [54] The database for 
opioid exposure is less robust than that for cocaine. [55] It is possible that there are subtle 
neurodevelopmental effects arising from in utero opioid exposure outside of effects due to 
environmental and home settings. [56] Even if real, however, these associations do not provide 
guidance about practical therapeutic decisions.  For newborns, the benefits of maternal opioid 
therapy during pregnancy using methadone in a structured program clearly outweigh no 
therapy.  There is evidence that un- or undertreated women may seek street sources of opioids 
to treat withdrawal symptoms, which clearly has negative neonatal outcomes.  Importantly, there 
is no evidence of long term adverse outcomes in children treated with pharmacologic agents vs. 
infants who do not require treatment for NAS, or for treatment with different classes of agents. 
[57, 58]  While the database of information is smaller, neonatal outcomes with in utero 
buprenorphine exposure are generally favorable compared to methadone in human and animal 
studies. [59]  
 
Current therapies 
Variability of current practice patterns 
Few studies have examined NAS prevalence and treatment patterns. Nandakumar 
published a survey of 17 neonatal units in the Northwest Region of the United Kingdom (UK) 
revealing not only conflicting practices in scoring, identification and management, but also a 
deficit of reliable data to assist practitioners in determining the best regimen to treat NAS. [60] 
While Sarkar conducted a U.S. survey in neonatal intensive care units (NICU), the focus was 
primarily on determining the percentage of respondents using an abstinence scoring system, 
those with access to formal written policies or educational programs for NAS management, and 
practitioners using customary pharmacologic agents for withdrawal. [61] The 13 question survey 
of 102 accredited fellowship programs (which had 75 respondents), did not include questions on 
NAS incidence or length of hospital stay.  O’Grady and colleagues conducted a 15 question 
questionnaire of 235 neonatal units that sought to survey current NAS practices in the UK and 
Ireland. [62] The survey assessed first and second line agents, attitudes to breastfeeding by 
women on methadone, and the safety of infants discharged on medication. Crocetti and 
colleagues assessed the number of opiate-exposed neonates that were identified having NAS, 
as well as policies and procedures for treatment in 27 hospitals throughout Maryland. [63] There 
are clear information gaps both for identification, treatment, and length of hospital stay. 
Moreover, there is lack of pharmaco-economic analyses on costs and cost effectiveness of 
treatment in NAS. 
 
Framework for treatment 
The therapeutic framework of treatment begins with the identification of infants at risk for 
NAS.  NAS is graded using a standard checklist that identifies and stratifies severity of disease 
based upon signs and symptoms in multiple domains.  Of a number of scoring systems used to 
gauge symptom severity and titrate drug dose, [64-66] the Finnegan score (or modifications of 
it) [67] is the most commonly used. [61, 62]  A modification of the Finnegan score used in the 
multicenter MOTHER study of buprenorphine use for pregnant women, [68, 69] is the standard 
instrument used in other randomized NAS research trials. [70, 71]  The Finnegan instrument 
was created to assess severity of disease in those with known opioid exposure.  However, on 
day 2 of life a score of 7 corresponds with the 95th percentile for non-exposed infants, meaning 
any score of 8 or greater is highly suggestive of in utero opioid exposure even in those denying 
opioid use during pregnancy. [72] Non-pharmacologic therapies should be employed for all 
infants with in utero opioid exposure.  These include swaddling, [73] the use of small calorically 
dense formulas, rooming in, breastfeeding, and minimization of excessive external stimulation.  
Infants with mild symptoms should be observed in the hospital for at least four days.  For infants 
with severe symptomatology manifested by seizures, poor weight gain, and elevated values in a 
NAS-specific scoring instrument, pharmacologic therapy is indicated.  Ideal treatment employs a 
protocol-driven use of drug titration to control symptoms.  Both symptom driven (i.e., weight-
independent fixed dose titration based upon severity of NAS scores) as well as weight-based 
dosing regimens, have been employed, with neither being identified as the standard approach. 
[74] Regardless of the manner of dose titration, infants who do not have control of symptoms 
despite high doses of the initial therapy are treated with a secondary drug.  After stabilization, 
symptom scores are used to gradually wean the controlling drug or drugs.  This occurs typically 
in an inpatient setting, as it allows careful observation and dose titration of infants.  Some 
institutions will stabilize an infant in an inpatient setting, with terminal weaning done as an 
outpatient.  The use of outpatient treatment in highly selected patients is associated with shorter 
inpatient stays, but extended total duration of therapy. [75]   
The rationale to use pharmacologic therapy is to ensure proper feeding and 
development, and foster the maternal infant bond.  The ideal specific drug used would safely 
achieve these therapeutic goals, while at the same time minimizing the total duration of therapy 
and length of hospitalization.  Most commonly employed initial therapy is an opioid, while 
commonly used adjunctive therapies are phenobarbital or clonidine.  Though used more 
commonly, phenobarbital has not been demonstrated to have improved safety or efficacy 
compared to clonidine as an adjunctive therapy.  A comparison of these agents as adjuncts is 
currently being investigated (NCT01175668).  The role of initial dual therapy of phenobarbital 
with an opioid has been described, but has not been compared in a large number of patients.  
[76] The value of this approach has not been established, but anecdotally may provide benefit in 
infants with poly-substance use. 
 
 Opioids 
Cochrane reviews, [77, 78] the American Academy of Pediatrics, [9, 79] and expert 
review [80, 81] identify opioid replacement as the ideal treatment for the withdrawal symptoms 
associated with in utero exposure to opiates.  Opioid replacement as a first line agent 1) 
improves weight gain but lengthens hospitalizations compared to supportive care, 2) reduces 
seizure rates and possibly duration of therapy compared to phenobarbital, and 3) reduces 
treatment failure compared to diazepam. [77] While many of the studies cited in the Cochrane 
review had methodological flaws, the standard of care practice which has developed since the 
1970s has generally supported this approach.  There is limited evidence with which definitive 
recommendations can be made regarding differential safety and efficacy of specific opioids.  
Moreover, high quality data on the optimal dose regimens or comparative effectiveness on use 
of adjunctive agents are lacking.  Current practice patterns for these have been developed 
empirically and remain an area that would benefit from higher quality investigations. 
 
Morphine 
 Morphine is the most commonly employed replacement therapy opioid.  Paregoric, a 
previously commonly used morphine source, was never subject to any formal FDA evaluation 
and is no longer available.  Diluted, deodorized tincture of opium (DTO) has a morphine 
concentration of 0.4 mg/ml and an ethanol concentration of 0.19%.  This has been largely 
replaced by an ethanol-free morphine solution of 0.4 mg/ml concentration.  Preservative-free 
morphine hydrochloride solution for neonatal administration is stable at 4 degrees C for at least 
6 months. [82] Due to the relatively short half-life of morphine, best outcomes have been 
demonstrated when morphine doses are given no longer than 4 hours apart. [83] Accordingly, 
infants who are sleeping at the nominal dose time should be awakened for drug administration. 
 Morphine in humans is metabolized primarily to morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G) via uridine 5’-diphisphate glucuronosyl transferase (UGT)-2B7.   
The ontogeny of UGT development is dynamic in the immediate postpartum period.  This is 
demonstrated by reduced M6G/morphine ratio in neonates younger than 7 days, as well as an 
associated reduced postsurgical morphine requirement compared to older neonates. [84] Non-
linear mixed effects models have been used to estimate both active metabolite formation as well 
as elimination. [85] Clearance generally correlates with glomerular filtration, with minimal fecal 
elimination or metabolism to normorphine.  The large inter- and intrapatient variability of 
intravenous morphine pharmacokinetics (PK) and pharmacodynamics (PD) in neonates is due 
in part to a dynamic acquisition of metabolic enzymes, renal function, and changes in fat and 
extracellular fluid balance. [84-86] Of note, the pharmacokinetics of orally administered 
morphine in neonates is currently unknown.  An area of therapeutic need would be the 
characterization of the concentration response relationship.  Such a relationship, created with 
modeling and simulation, would be of utility in designing an optimized dose regimen. 
The initial dose of morphine is 0.12-0.6 mg/kg/day in a survey of 17 pediatric units in the 
United Kingdom. [60] The authors of this report had the opinion that a higher initial dose may be 
associated with better control of symptoms, but acknowledged that evidence to support this 
intuition was lacking.  A dose of 0.24 mg/kg/day was recommended by the 1998 report of the 
American Academy of Pediatrics (AAP), [9] though this protocol outlined drop unit doses which 
would make fine titration difficult.  Neither the 2012 AAP Committee on Drugs NAS report [79] 
nor the Cochrane review of the topic identify a favored specific dose. [77] There is no generally 
accepted maximum dose of morphine used for NAS.  A survey of neonatal units in the UK 
revealed that typical maximum doses were up to 1.3 mg/kg/day, and that one third determined 
dose according to symptom control rather than a maximum predefined level. [62] Specific 
protocols for dose titration are based either on a weight-based increase in dose based upon 
scores above a specific NAS score, or a weight-independent dose base upon a graded severity 
of NAS score. Table 1 provides two commonly employed approaches.  
 
Methadone 
 Methadone is a long acting opioid commonly used for abstinence treatment.   The longer 
half-life of methadone provides less of a flux between peak and trough levels, while also 
providing ease of administration at less frequent intervals.  Oral bioavailability in adults is high, 
but variable. [87] The pharmacokinetics of methadone in the pediatric and neonatal populations 
has been simulated using physiologic based pharmacokinetic modeling which suggests 
significant inter-patient and developmental variability, but decreased systemic exposure with 
age. [88] This model has not been validated by rich patient-level data.  There is scant published 
clinical trial evidence to guide use in the neonatal population.  In a single small study, outcomes 
with methadone were similar to phenobarbital or diazepam. [89] Comparisons with oral 
morphine are limited to a single retrospective review of 46 patients, in which there was no 
significant difference in length of stay between treatments. [90] A standard dose has not been 
established, but the protocol employed by Lainwala is provided in Table 2.  Methadone use 
remains relatively uncommon, ranging from <2% of units in the UK, [62] to as high at 20% in the 
US. [61] The extended dosing interval has led some sites to use methadone as extended 
outpatient dosing.  Compared to full inpatient treatment, infants discharged home on methadone 
have shorter hospitalizations, but longer duration of therapy, though at least in one study had 
similar total mg of methadone administered. [91] Because of the likely variability of 
pharmacokinetics, frequent outpatient follow up is required to allow careful monitoring and dose 
titration based upon symptoms. 
 
Buprenorphine 
 Buprenorphine is a long acting partial mu opioid receptor agonist that in adults is more 
effective for withdrawal symptoms than clonidine, and possibly methadone. [92] Use of 
buprenorphine in this population has gained favor in part due to properties of improved safety, 
particularly with regard to respiratory depression.  Buprenorphine has compared favorably to 
methadone for use in pregnant women. [24] In NAS, the use of buprenorphine has been 
explored in two open label, placebo controlled trials.  [70, 93] A total of 50 infants were 
randomized in a 1:1 ratio to oral morphine every four hours or sublingual buprenorphine 
administered every 8 hours.  The optimized initial dose was 15.9 mcg/kg/day, with a maximum 
of 60 mcg/kg/day.  Doses were increased 25% until control of symptoms was obtained, and 
decreased by 10% until cessation of therapy when the dose was 10% of the initial dose.  Doses 
were not adjusted for actual weight, and were instead based upon the weight at initiation of 
therapy.  While the initial goals of this phase 1 investigation was the feasibility and safety of 
buprenorphine to treat NAS, an efficacy advantage over morphine was demonstrated.  When 
the results from both cohorts were combined, treatment with buprenorphine revealed a mean 
length of treatment of 23 days, as compared with a mean length of 34 days using standard of 
care oral morphine (Figure 1).  Following log transformation to satisfy normality assumptions, 
the length of treatment was on average 36% shorter (95% CI: 17%, 51%; p=0.001) in the 
buprenorphine arm than in those administered oral morphine, and the length of stay was on 
average 29% shorter (95% CI: 10%, 44%; p=0.006).  Caveats to these findings are an open 
label study design and that while consistent with retrospective studies at the same institution, 
[34] the duration of treatment and length of stay in both arms was somewhat longer than has 
been reported at other institutions. 
Adjunctive therapy with phenobarbital was required in 6 of 25 infants in the 
buprenorphine group compared to 2 of 25 randomized to morphine.  It is unclear if this finding is 
due to a ceiling effect of buprenorphine as a partial agonist in a subset of patients with more 
severe disease, or if the predefined maximum dose of buprenorphine was set too low.  
Pharmacokinetic sampling in this trial unexpectedly revealed  amelioration of withdrawal 
symptoms at plasma concentrations of buprenorphine below the 0.7 ng/ml threshold, estimated 
for relief of symptoms in adults. [94] This could be a factor of a different volume of distribution of 
the drug in the neonate, or a pharmacodynamic profile of withdrawal that fundamentally differs 
from that in adults. 
Drug for sublingual administration are formulated using buprenorphine for injection 
(Buprenex or equivalent genetic) at a concentration of 0.075 mg/ml in a 30% ethanol solution.  
Buprenorphine is stable at room temperature for at least 30 days in glass vials, and for at least 7 
days in plastic syringes. (Anagnostis, article in press)  Buprenorphine is absorbed by the 
sublingual route within two minutes in adults.  There was no evidence of aspiration in neonates 
after > 1,600 individual doses were administered in the Phase 1 investigation.  There were two 
serious adverse events.  One infant developed cytomegalovirus in the immediate post partum 
period, and another had idiopathic seizure.  Both events judged to be unrelated to study 
treatment by the investigator, IRB and data safety monitoring board.   
  
 Adjuncts 
Phenobarbital  
The use of phenobarbital (identified as phenobarbitone in the British nomenclature) is 
often used as a rescue therapy when maximum opioid replacement therapy dose is reached 
without adequate resolution of symptoms, though it has also been used as an initial adjunct in 
combination therapy with an opioid [76] or as initial monotherapy. [95] Phenobarbital use has 
been examined in a Cochrane review, in which the conclusion was that opioids had a 
comparative  advantage incidence of seizures, duration of treatment and nursery admissions, 
but not necessarily in the treatment failure rate. [78] The half-life of phenobarbital in neonates 
decreases from 115 hours after 1 week to 67 hours after 4 weeks. [96] This prolonged half-life 
explains the improved outcomes through the use of a loading dose compared dosing without a 
load. [97] The typical loading dose is 20 mg/kg, followed by 5 mg/kg.  Phenobarbital anecdotally 
appears to have particular utility in those infants with poly-drug exposure in utero.  
Phenobarbital causes increased metabolism of many drugs metabolized by the cytochrome 
P450 system for patients of all agents, a finding which was confirmed in NAS infants co-treated 
with phenobarbital and buprenorphine. [98] Questions raised about the potential for deleterious 
neurodevelopmental effects will be addressed by the ongoing PROPHENO trial (NCT 
01089504), scheduled to be completed in late 2014.  
 
Clonidine 
Clonidine is a centrally acting alpha agonist that reduces global sympathetic tone and 
has been used in adult withdrawal syndromes.  Clonidine is less efficacious in adults as 
compared to an opioid in the management of withdrawal symptoms. [92] A number of small 
retrospective examinations had suggested clonidine as a useful adjunct therapy in NAS. (Table 
3)  Agthe described a high quality, randomized controlled trial of clonidine1 µg/kg every 4 hours 
compared to placebo as a parallel adjunct to oral morphine therapy (in the form of DTO).  
Clonidine solution for epidural injection (100 µg/mL) was diluted to 5 µg/mL and administered 
orally.  The dual morphine/clonidine arm had statistically significantly shorter length of stay (11 
days [95% CI: 8–15] vs 15 days [95% CI: 13–17]).  In addition, total dose of morphine was 7.7 
mg with dual therapy compared to 19.2 mg with monotherapy (p=0.03).  Clonidine was 
generally well tolerated, with no serious hypotension or bradycardia.  An episode of 
supraventricular tachycardia occurred in one patient three days after cessation of clonidine.  
Based upon the mechanism of action of clonidine and potential for post cessation sympathetic 
surge, it is plausible that this was causally related to cessation of study drug.  Three infants in 
the clonidine treated group died of autopsy verified myocarditis, SIDS, and homicide 
(methadone overdose).  Each occurred at least 22 days after the cessation of study drug and 
were assessed to be not related to study drug.  Xie performed nonlinear mixed effects modeling 
of clonidine pharmacokinetics and noted a rapid increase in clearance in the first month of life.  
A dose adjustment of 1.5 µg/kg every 4 hours starting the second week of life, based upon 
modeling and simulation, was proposed.  [99] This dose adjustment has not been tested in a 
clinical trial setting. 
 
Breast feeding 
The number of females in methadone programs who choose to breastfeed their 
newborns has been traditionally low, with more than half of those who start, stopping after 6 
days. [100] It is however, expected that this number will increase both locally and nationwide 
due to specific campaigns.  In 2011, the United States Surgeon General released A Call to 
Action to Support Breastfeeding, which calls for expansion of breastfeeding for American 
infants.  This is a position supported by the Department of Health and Human Services in 
Healthy People 2020, as well as major medical societies. [101] Methadone is passed on to 
neonates through breast milk, though the absolute amount is small (<0.2 mg/day) and does not 
appreciably change neonatal serum methadone concentrations. [102] However, a 
pharmacodynamic effect is suggested, as breastfed infants have decreased severity of NAS or 
need for treatment with pharmacologic agents. [103, 104] Based upon the small doses of drug 
transferred to the infant, it is not clear if this effect reflects the calming effect of the act of 
breastfeeding or drug effect. [105] For mothers maintained on usual abstinence doses, the 
amount of breast milk transferred buprenorphine is 0.1-1.2 mcg/kg/day, which represents 
~0.02% of the maternal dose.  [106-109] The bioavailability of buprenorphine transferred in 
breast milk is not characterized, but appears low based upon measurement in neonatal blood 
and urine, [109] and by minimal effects in suppression of NAS symptomatology.  [110-112] 
There are no reported safety concerns associated with breastfeeding, and so, despite the 
product insert which advises against breastfeeding, current national guidelines advocate 
breastfeeding for mothers prescribed buprenorphine. [113]  
 
Pharmacogenetics 
The inter-patient variability seen in severity of withdrawal symptoms or response to 
therapies cannot be reduced to a monogenic etiology in either newborns or adults.  However, 
several single nucleotide polymorphisms (SNPs) in particular candidate genes, have been 
identified that appear to determine response to opioids for pain or replacement abstinence 
therapy in adults, for predilection to substance abuse disorder, [114] and social hedonic 
capacity. [115] The mu opioid receptor (OPRM1) gene A118G SNP has been associated with 
differential morphine sensitivity, with decreased pain and morphine requirements with the AA 
genotype. [116]  An exploratory examination by Wachman in 28 term infants with in utero opioid 
exposure revealed a significantly lower need for pharmacotherapy, lower doses and shorter 
lengths of stay in patients with the AA variant compared to GG. [100] Catechol-O-
methyltransferase (COMT), an enzyme that degrades catecholamines, was also examined.  In 
adults, the COMT SNP (Val158Met) is associated with a lower required morphine dosage in 
cancer patients, [117] although the association with addiction is much less clear. [118]  
Wachman reported that COMT (Val158Met) was associated with decreased need for therapy, 
dose of medications and length of stay.  Variants of p-glycoprotein (MDR1) were not associated 
with differential NAS outcomes.  These intriguing findings, if verified in a larger cohort, may have 
implications for identifying those most at risk for the need of therapy.  Enthusiasm is tempered, 
however, by the example of pharmacogenetic approaches to warfarin therapy in adults, in which 
there is limited practitioner uptake despite evidence of efficacy and easy to use algorithms. 
 
Future Directions 
Future directions may include the examination of the existing scales, particularly those 
based upon the Finnegan, to see if there is an ability to simplify the scales to include those 
elements most closely correlated with clinical outcomes in the management of infants with 
known opioid exposure.  A 3 point scale consisting of hyperactive Moro reflex, mild tremors 
when undisturbed, and increased muscle tone has been described as discriminative between 
opioid and non-opioid exposed infants, but this has not yet been validated in a large sample. 
[24] 
Dexmedetomidine is chemically similar to clonidine, but with a greater alpha 2 receptor 
specificity. [119] Dexmedetomidine has been proposed as a potential alternative for the 
treatment of iatrogenic pediatric opioid withdrawal syndromes, but has not been evaluated in the 
treatment of NAS. [120]  Lofexidine and guanfacine are other alpha 2 agonists which have been 
investigated for the treatment of adult but not pediatric withdrawal, but the size and quality of 
studies have been limited. [121] These agents have no theoretic advantage over clonidine. 
 It is not clear if a short acting agent such as morphine compared to longer half-life drugs 
such as buprenorphine or methadone will provide better outcomes for infants who require 
pharmacologic therapy.  Extrapolation from adult abstinence and control of withdrawal 
symptoms would suggest that longer acting agents, by reducing the flux in drug concentration, 
would provide more uniform control of symptoms and a smoother transition to the post-
cessation of therapy period.  However it is also possible that morphine would provide more 
flexibility in titrating to a dynamic symptom complex by allowing quicker dose titration and 
attainment of steady state after dose adjustment.  A double blinded, double dummy trial 
currently underway may provide insight into this question. (NCT01452789) 
 The majority of treatment for NAS takes place in an inpatient setting, but there are 
institutions in which home management with phenobarbital and methadone are employed.  A 
formal comparison between these approaches would be useful.  The correct location for 
treatment also needs to take into consideration not only the pharmacology of the replacement 
agent, but also the dynamics of mother-infant dyad, and of the social situation.  In this way, any 
investigation should take these considerations into account in structuring a study, as well as in 
defining endpoints for examination.  
Pharmacogenetics may assist in identifying infants at risk for requiring pharmacologic 
therapy for NAS, but likely be only one of many covariates which would feed into a predictive 
disease state model.  Such a model could effectively link demographics, in utero exposures, 
disease severity, genetic factors, pharmacodynamic responses, pharmacokinetics, and other 
variables.  It is likely that such a model would be actuated optimally in an electronic system that 
had system inputs from an electronic medical record.  Modeling also will play an increasing role 
in bringing quantitative methods allowing to use the sparse data sets available in neonates.  In 
such a fashion, pharmacometric simulations can predict dose response and help to inform 
formulation of new dosing regimens or combination therapy.  Using a “lean and confirm” 
paradigm, these models can be refined and optimized. [122] 
 
Conclusions 
Clearly, there is an unmet medical need to develop improved pharmacologic treatment 
for infants with NAS.  The mean hospital cost for an NAS admission in 2009 was $53,400. [21] 
Ideally, such treatment would provide improved symptom control without compromising safety, 
and would shorten treatment duration and length of hospital stay.  If widely adopted, a treatment 
with these features would have the potential to decrease resource utilization and costs of 
treating NAS, as well as to improve psychosocial and developmental outcomes in infants 
exposed to opioids in utero.  
 
 
 
 
  
Table 1. Morphine Regimens 
Regimens are based upon Finnegan Scoring every 4 hours. 
Weight based Symptom based  [69, 123] 
Initial dose:  
• 0.4 mg/kg/day in 6 divided doses 
  
Dose Increase:   
• 20%/day for NAS scores > 24 total 
on three measures, or a single 
score ≥ 12.   
 
Weaning Dose:  
• After 48 hours of clinical stability, 
reduce dose by 10% every 24-48 
hours  
• Reduce dose when the sum of the 
previous three scores is < 18 and 
no single score is > 8.   
• Cease therapy when dose is 0.15 
mg/kg/day. 
 
Rescue dose:  
• Administer additional morphine at 
previous dose for inadequate 
symptom control between 
scheduled dose intervals. 
 
Adjunctive treatment:  
• At dose of morphine 1.25 
mg/kg/day initiate second 
medication * 
 
Initial dose:  
For first elevated score >8, rescore in one 
hour to verify.  If still elevated: 
Single NAS score Dose q4hr 
9-12 0.04 mg 
13-16 0.08 mg 
17-20 0.12 mg 
21-24 0.16 mg 
>25 0.20 mg 
Doses are fixed and not based upon infant 
weight 
 
Dose Increase:   
Single NAS score Increase  Dose 
0-9 none 
9-12 0.02 mg 
13-16 0.04 mg 
17-20 0.06 mg 
 
Weaning Dose:  
• After 48 hours of clinical stability, 
reduce dose by 0.02 mg every 24 
hours if scores <8 
 
• For first elevated score >8, rescore 
in one hour to verify.  If still elevated 
 
Two NAS scores Increase Dose 
9-12 0.01 mg 
13-16 0.02 mg 
17-20 0.04 mg 
 • Cease therapy when dose is 0.02 
mg 
 
Adjunctive treatment:  
At dose of morphine 1.6 mg/day initiate 
second medication* 
 
*phenobarbital loading dose of 20 mg/kg followed by 5 mg/kg/day OR clonidine 
 
  
Table 2: Methadone protocol for inpatient use 
● Initial loading dose 0.1 mg/kg/dose  
● Additional 0.025 mg/kg/dose given every 4 hr for continuing NAS scores >8 until 
symptoms controlled or maximum dose of 0.5 mg/kg/day reached 
● Maintenance dose determined by calculating the total methadone dose given over 
previous 24 hours 
● Maintenance dose administered in 2 divided doses every 12 hours 
Source: [90] 
 
  
Table 3: Clonidine Use 
Year  n Clonidine dose (mcg/kg) 
Outcome in Length of Stay 
(LOS) or Length of Treatment 
(LOT) 
Hoder, 
1984 
[124] 
Case Series 7 0.5–1.0 po Q 6 hr 13 day LOS 
Leikin, 
2009 
[125] 
Case Series 14 0.5–1.0 po Q 6 hr 
7 day LOT 
In utero exposures = 3 
Iatrogenic NAS = 11 
Esmaeili, 
2010 
[126] 
Case Series 29 0.5–3.0 hr IV  
14 day LOT 
32 day LOS 
Chloral hydrate rescue 
Agthe, 
2009 [71] 
Randomized 
Controlled 
Trial 
40 1.0 po Q 4 hr (+ 
morphine) 11 day LOT vs. 15 for placebo 
 
  
Figure Legend 
 
Length of Treatment: Open Label Morphine vs. Buprenorphine by Patient 
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